Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saci-IO HR+: Sacituzumab Govitecan with or without Pembrolizumab in HR+/HER2- MBC
NCT04448886Phase 2Active, not recruiting
- Sponsor
- Ana C. Garrido-Castro
- Start
- Sep 2020
- Primary completion
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in breast cancer, sponsored by Ana C. Garrido-Castro. Started Sep 2020; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04448886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04448886.